Skip to main content

Advertisement

Log in

Amphetamine alters an EEG marker of reward processing in humans and mice

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The bench-to-bedside development of pro-cognitive therapeutics for psychiatric disorders has been mired by translational failures. This is, in part, due to the absence of pharmacologically sensitive cognitive biomarkers common to humans and rodents. Here, we describe a cross-species translational marker of reward processing that is sensitive to the aminergic agonist, d-amphetamine. Motivated by human electroencephalographic (EEG) findings, we recently reported that frontal midline delta-band power is an electrophysiological biomarker of reward surprise in humans and in mice. In the current series of experiments, we determined the impact of parametric doses of d-amphetamine on this reward-related EEG response from humans (n = 23) and mice (n = 28) performing a probabilistic learning task. In humans, d-amphetamine (placebo, 10 mg, 20 mg) boosted the Reward Positivity event-related potential (ERP) component as well as the spectral delta-band representations of this signal. In mice, d-amphetamine (placebo, 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg) boosted both reward and punishment ERP features, yet there was no modulation of spectral activities. In sum, the present results confirm the role of dopamine in the generation of the Reward Positivity in humans, and pave the way toward a pharmacologically valid biomarker of reward sensitivity across species.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

All data and Matlab code to re-create these analyses are available at OpenNeuro.org, accession #ds003987.

References

Download references

Funding

The project was funded by NIMH UH3 MH109168.

Author information

Authors and Affiliations

Authors

Contributions

JFC: Conceptualization, Methodology, Software, Formal analysis, Writing—Original Draft, Funding acquisition.

SLO: Investigation.

JAT: Investigation, Data curation, Supervision, Project Administration.

JEK: Investigation, Data curation, Supervision, Project Administration.

BZR: Investigation, Data curation, Supervision, Project Administration.

JAN: Investigation, Data curation, Supervision, Project Administration.

JS: Investigation, Data curation, Supervision, Project Administration.

DG: Investigation.

SGB: Conceptualization, Methodology, Investigation, Data curation, Supervision, Project Administration, Writing—Review & Editing, Funding acquisition.

GAL: Conceptualization, Methodology, Resources, Writing—Review & Editing, Funding acquisition.

NRS: Conceptualization, Methodology, Writing—Review & Editing, Investigation, Data curation, Supervision, Project Administration, Funding acquisition.

JWY: Conceptualization, Methodology, Writing—Review & Editing, Funding acquisition.

JLB: Conceptualization, Methodology, Resources, Writing—Review & Editing, Funding acquisition.

Corresponding author

Correspondence to James F. Cavanagh.

Ethics declarations

Conflict of interest

JWY has received pharmaceutical funding from Sunovion Pharmaceuticals unrelated to the current work. All other authors report no biomedical financial interests of potential conflicts of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 557 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cavanagh, J.F., Olguin, S.L., Talledo, J.A. et al. Amphetamine alters an EEG marker of reward processing in humans and mice. Psychopharmacology 239, 923–933 (2022). https://doi.org/10.1007/s00213-022-06082-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-022-06082-z

Keywords

Navigation